HilleVax (HLVX) Competitors $1.90 +0.01 (+0.53%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends HLVX vs. NMRA, ORGO, AURA, KALV, ETON, PRME, VALN, KRRO, ENGN, and GLUEShould you be buying HilleVax stock or one of its competitors? The main competitors of HilleVax include Neumora Therapeutics (NMRA), Organogenesis (ORGO), Aura Biosciences (AURA), KalVista Pharmaceuticals (KALV), Eton Pharmaceuticals (ETON), Prime Medicine (PRME), Valneva (VALN), Korro Bio (KRRO), enGene (ENGN), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. HilleVax vs. Neumora Therapeutics Organogenesis Aura Biosciences KalVista Pharmaceuticals Eton Pharmaceuticals Prime Medicine Valneva Korro Bio enGene Monte Rosa Therapeutics HilleVax (NASDAQ:HLVX) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability. Do analysts prefer HLVX or NMRA? HilleVax presently has a consensus target price of $3.00, indicating a potential upside of 57.89%. Neumora Therapeutics has a consensus target price of $16.50, indicating a potential upside of 704.88%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than HilleVax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HilleVax 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Neumora Therapeutics 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has preferable earnings & valuation, HLVX or NMRA? Neumora Therapeutics is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHilleVaxN/AN/A-$123.57M-$3.10-0.61Neumora TherapeuticsN/AN/A-$235.93M-$1.87-1.10 Is HLVX or NMRA more profitable? HilleVax's return on equity of -67.27% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets HilleVaxN/A -67.27% -51.99% Neumora Therapeutics N/A -73.63%-68.97% Do insiders and institutionals believe in HLVX or NMRA? 86.4% of HilleVax shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 71.1% of HilleVax shares are held by company insiders. Comparatively, 26.4% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to HLVX or NMRA? In the previous week, Neumora Therapeutics had 4 more articles in the media than HilleVax. MarketBeat recorded 4 mentions for Neumora Therapeutics and 0 mentions for HilleVax. Neumora Therapeutics' average media sentiment score of 0.06 beat HilleVax's score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment HilleVax Neutral Neumora Therapeutics Neutral Does the MarketBeat Community believe in HLVX or NMRA? Neumora Therapeutics received 15 more outperform votes than HilleVax when rated by MarketBeat users. Likewise, 89.29% of users gave Neumora Therapeutics an outperform vote while only 58.82% of users gave HilleVax an outperform vote. CompanyUnderperformOutperformHilleVaxOutperform Votes1058.82% Underperform Votes741.18% Neumora TherapeuticsOutperform Votes2589.29% Underperform Votes310.71% Which has more risk and volatility, HLVX or NMRA? HilleVax has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.71, indicating that its stock price is 171% more volatile than the S&P 500. SummaryNeumora Therapeutics beats HilleVax on 9 of the 15 factors compared between the two stocks. Get HilleVax News Delivered to You Automatically Sign up to receive the latest news and ratings for HLVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HLVX vs. The Competition Export to ExcelMetricHilleVaxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.10M$2.95B$5.22B$8.94BDividend YieldN/A1.94%5.13%4.04%P/E Ratio-0.6145.5689.7217.34Price / SalesN/A263.271,251.2178.56Price / CashN/A192.9043.8235.97Price / Book0.353.965.324.79Net Income-$123.57M-$41.02M$122.69M$225.00M7 Day Performance-7.32%-1.74%-0.16%1.52%1 Month Performance2.15%0.53%3.75%4.68%1 Year Performance-86.94%-1.69%27.41%20.89% HilleVax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HLVXHilleVax2.073 of 5 stars$1.90+0.5%$3.00+57.9%-87.2%$102.10MN/A-0.6120Gap UpNMRANeumora Therapeutics3.79 of 5 stars$2.42+9.5%$16.50+581.8%-85.5%$390.98MN/A-1.29108Analyst ForecastORGOOrganogenesis4.3321 of 5 stars$3.00-0.3%$5.00+66.7%-13.7%$377.18M$455.04M-50.00950News CoveragePositive NewsAURAAura Biosciences2.5911 of 5 stars$7.50-1.3%$23.00+206.7%-1.0%$374.63MN/A-4.3450Short Interest ↑News CoveragePositive NewsKALVKalVista Pharmaceuticals4.3348 of 5 stars$7.52-4.2%$25.00+232.4%-36.2%$371.62MN/A-2.07150ETONEton Pharmaceuticals3.486 of 5 stars$14.00+4.2%$18.67+33.3%+248.1%$364.71M$34.68M-63.6420Short Interest ↓PRMEPrime Medicine3.8447 of 5 stars$2.77-5.8%$12.67+357.3%-57.5%$363.32M$800,000.00-1.35234Analyst UpgradeGap DownVALNValneva3.0078 of 5 stars$4.44-2.2%$18.50+316.7%-51.8%$360.80M$158.54M-34.15700Short Interest ↓Positive NewsKRROKorro Bio2.3841 of 5 stars$38.15+8.2%$144.00+277.5%-15.2%$357.39M$14.07M0.0070Short Interest ↑News CoverageENGNenGene2.4198 of 5 stars$8.06+5.9%$29.78+269.5%-4.8%$356.38MN/A-13.9031Short Interest ↑News CoverageGap DownGLUEMonte Rosa Therapeutics2.4273 of 5 stars$5.66-0.7%$14.00+147.3%+7.0%$347.73M$14.98M-3.0990Short Interest ↑ Related Companies and Tools Related Companies NMRA Competitors ORGO Competitors AURA Competitors KALV Competitors ETON Competitors PRME Competitors VALN Competitors KRRO Competitors ENGN Competitors GLUE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HLVX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HilleVax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HilleVax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HLVX Stock Alerts